Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Lisaftoclax + BTK inhibitor
- Development stage
- Unknown
- Lead developer
- Ascentage Pharma
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Lisaftoclax + BTK inhibitor refers to the investigational combination of lisaftoclax, a novel, orally administered small-molecule BCL-2 selective inhibitor, with a Bruton’s tyrosine kinase (BTK) inhibitor such as acalabrutinib. Lisaftoclax is designed to selectively block the antiapoptotic protein BCL-2, restoring apoptosis in cancer cells and thereby treating hematologic malignancies like chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL). The drug features a short half-life that allows for rapid daily dose ramp-up and has demonstrated promising efficacy and safety both as monotherapy and in combination regimens. The combination with BTK inhibitors is being evaluated in global phase 3 clinical trials for patients with CLL/SLL who have received prior therapies, including those previously treated with venetoclax or other BTK inhibitors[1][2][3][8].
- Other names
- lisaftoclax + BTK inhibitor
02
Targets
BCL-2 (BCL-2 family)BTK (Bruton tyrosine kinase)
Beyond the preview
Go deeper on Lisaftoclax + BTK inhibitor.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Lisaftoclax + BTK inhibitor.